Abstract:Abstract The use of different liquid biopsy tools including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown great promise for the use in personalized cancer diagnostics, treatment monitoring, and research, especially among metastatic patients. The power of ctDNA analyses in early detection of acquired resistance against e.g. EGFR-targeted therapies in non-small cell lung cancer (NSCLC) have been demonstrated in several studies. However, NSCLC patients display lower ctDNA and CTC concentrations than expected and in particular brain metastases pose a challenge, probably due to the blood-brain barrier. In this study, we used a novel highly sensitive assay to detect clinically relevant mutations in ctDNA and detected CTCs in blood from metastatic NSCLC patients. 56 metastatic NSCLC cases were enrolled in this study. 37 patients presented with brain metastases and 20 of them had brain as the only site of metastasis (oligo-metastatic disease). Cell free (cf)DNA was isolated from 1.5-2ml of plasma using the Circulating Nucleic Acid kit (Qiagen). The ctDNA quantity was measured by Qubit Fluorometer (Thermo Fisher) and the quality was assessed by Tapestation (Agilent technologies). The UltraSEEK™ Lung Panel on the MassARRAY® System (Agena Bioscience) was used for the detection of mutations in five genes EGFR, KRAS, BRAF, ERBB2 and PIK3CA covering 67 different hot spot mutation loci. CTCs were detected by the CellSearch system. The total cfDNA concentration yields were low in most cases (median; 21ng/30µl, mean; 39ng/30µl, ± SD 2.6 ng/µl isolated from 1.5-2ml of plasma). Mutations could be detected in 26 samples (46.4%), with the variant allele frequency ranging between 0.1% and 5%. EGFR mutations were detected in 23.2% (13/56), KRAS in 21.4%, ERBB2 in 7.1%, PIK3CA in 3.6% and BRAF in 1.8% of the samples. Mutations were detected in 57.9% of patients with peripheral (non-brain) metastases, whereas 40.5% of brain metastatic patients had mutations detected in blood. Among oligo-metastatic patients, 30.5% had detectable mutations in plasma. In 42 samples, the EGFR mutation status in the primary tumor tissue was also determined. In 90.5% of samples, concordant results between plasma and tissue were found. In two patients, an EGFR mutation was only detected in the plasma, whereas in two other samples the mutation was only detected in the tumor tissue. In 46 patients, CTCs were measured. In 11 patients (23.9%), ≥ 1 CTC was detected. In 64.7% of patients, an informative result was obtained when results from both liquid biopsy approaches were combined. The UltraSEEK technology was able to detect mutations in cfDNA in plasma from NSCLC patients with limited, oligo-metastatic tumor burden, low amounts of total cfDNA, and very low fractions of ctDNA. Parallel assessment of CTCs in patients without detectable ctDNA enlarged the population of patients amenable to successful liquid biopsy analysis. Citation Format: Harriet Wikman, Malte Mohme, Melanie Janning, Alexander Sartori, Katrin Lamszus, Sabine Riethdorf, Darryl Irwin, Manfred Westphal, Sonja Loges, Klaus Pantel. Clinical validation of a highly sensitive assay to detect mutations in plasma from advanced lung adenocarcinoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5581.

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA

Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in NSCLC

Abstract 5038: Validation of a comprehensive next-generation sequencing liquid biopsy assay for clinical diagnostics and clinical trial applications

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Longitudinal and Personalized Detection of Circulating Tumor DNA (ctdna) for Monitoring Efficacy of Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma (HCC).

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA

Validation of a Pan-Cancer NGS Liquid Biopsy Test for Routine Hospital Use: An International Multicenter Clinical Performance Evaluation

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

Abstract 5581: Clinical validation of a highly sensitive assay to detect mutations in plasma from advanced lung adenocarcinoma patients

Abstract 3448: A novel liquid biopsy lung cancer detection method using a coverage and fragment end motif machine learning analysis

Analytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing: An International Multicenter Study

CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.

B-361 Novel Blood-based Assay for Early Cancer Detection Demonstrates High Precision and Reproducibility on Low Tumor Content

Lab validation of an ultrasensitive ctDNA pan-cancer MRD assay using whole-genome sequencing.

Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results

Comprehensive detection of ctDNA variants at 0.1% allelic frequency using a broad targeted NGS panel for liquid biopsy research.

Biom-59. Individualized Tumor-Specific Amplified Dna Junctions For Plasma-Based Monitoring In Patients With High-Grade Gliomas

Clinical Utility of an Ultra-Sensitive Ctdna NGS Assay for the Detection and Monitoring in HR-positive, HER2-negative Breast Cancer.

Analytical validation of a novel multi-target blood-based test to detect hepatocellular carcinoma

Abstract 252: A single-tube approach for detection of circulating tumor DNA using customized panels

Liquid biopsy in the clinic: A prospective study of plasma circulating tumor DNA (ctDNA) next generation sequencing (NGS) in patients with advanced non-small cell lung cancers to match targeted therapy.